E Fund Management Co. Ltd. Boosts Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

E Fund Management Co. Ltd. increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 44.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,519 shares of the biotechnology company’s stock after acquiring an additional 1,705 shares during the period. E Fund Management Co. Ltd.’s holdings in Sarepta Therapeutics were worth $532,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after acquiring an additional 41,465 shares in the last quarter. Wellington Management Group LLP raised its holdings in Sarepta Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 3,909,800 shares of the biotechnology company’s stock worth $473,946,000 after purchasing an additional 54,698 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in Sarepta Therapeutics by 40.1% during the third quarter. Westfield Capital Management Co. LP now owns 806,400 shares of the biotechnology company’s stock valued at $97,752,000 after buying an additional 230,618 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 2.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 576,412 shares of the biotechnology company’s stock valued at $55,583,000 after buying an additional 16,061 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Sarepta Therapeutics by 29.8% in the 3rd quarter. Barclays PLC now owns 517,286 shares of the biotechnology company’s stock worth $62,705,000 after buying an additional 118,761 shares during the period. Institutional investors own 86.68% of the company’s stock.

Insider Activity

In other news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total value of $385,479.60. Following the completion of the sale, the director now owns 6,621 shares of the company’s stock, valued at $814,118.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,731 shares of company stock worth $3,248,319. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Trading Down 2.5 %

Sarepta Therapeutics stock traded down $3.46 during mid-day trading on Wednesday, hitting $132.58. The company’s stock had a trading volume of 1,579,019 shares, compared to its average volume of 1,032,851. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $159.89. The stock has a market cap of $12.53 billion, a PE ratio of 1,205.27 and a beta of 0.95. The company has a 50 day moving average of $125.37 and a 200-day moving average of $111.22. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same quarter in the previous year, the firm posted ($1.44) earnings per share. The company’s revenue was up 63.1% on a year-over-year basis. On average, research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.23 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SRPT. Needham & Company LLC reissued a “buy” rating and set a $166.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued a “neutral” rating and issued a $128.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, May 2nd. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Citigroup lifted their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, UBS Group increased their target price on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $160.60.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.